Trial Profile
An Open-label, Single-arm, Multi-centre, Long-term Extension Trial to Evaluate the Safety and Efficacy of Tralokinumab in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Clinical Trials
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Tralokinumab (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Registrational
- Acronyms ECZTEND
- Sponsors LEO Pharma
- 06 Mar 2024 Planned End Date changed from 5 Jul 2025 to 13 Jun 2025.
- 06 Mar 2024 Planned primary completion date changed from 14 Jun 2024 to 28 Jun 2024.
- 06 Mar 2024 According to a LEO Pharma media release, data from this study will be shared as an e-poster summarizing results at the upcoming 82nd American Academy of Dermatology (AAD) Annual Meeting.